LifeStance Health Group (LFST) Stock Overview
Through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LFST Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LifeStance Health Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.98 |
| 52 Week High | US$9.11 |
| 52 Week Low | US$3.74 |
| Beta | 1.19 |
| 1 Month Change | 21.52% |
| 3 Month Change | 39.22% |
| 1 Year Change | 81.05% |
| 3 Year Change | 0.22% |
| 5 Year Change | -68.21% |
| Change since IPO | -59.00% |
Recent News & Updates
Analysis Article • Jun 21
LifeStance Health Group (LFST) Stock Could Be 20% Undervalued After Zacks Rank Upgrade
The latest Zacks upgrade of LifeStance Health Group (LFST) to Rank #1, combined with higher earnings estimates, stronger recent financial results, and rising institutional ownership, has pushed this behavioral health stock firmly into the spotlight. See our latest analysis for LifeStance Health Group. LifeStance Health Group’s recent Zacks Rank upgrade comes alongside strong momentum, with a 30 day share price return of 21.52% and a 1 year total shareholder return of 85.92%, although longer...
Narrative Update • Jun 17
LFST: Future Earnings Power Will Rely On Clinician Scale And Technology
Analysts have made a small, neutral adjustment to their price target on LifeStance Health Group to $13.00, reflecting updated assumptions around revenue growth, profit margins and the stock’s projected P/E multiple. What’s in the News for LifeStance Health Group LifeStance Health Group reported Q1 2026 revenue of US$403.5 million, about 21% growth, with net income of US$14.2 million, supported by higher visit volumes, improved clinician productivity and demand for mental health services.Narrative Update • Jun 03
LFST: Future Earnings Power Will Rely On Scalable Clinical Outcomes
Analysts have raised their price target for LifeStance Health Group from $12 to $13, citing updated assumptions around discount rates, profit margins, and future P/E that change their view of the stock's valuation profile. What's in the News Q1 2026 results: Revenue of about US$403.5 million, up 21.2% year over year, with net income of US$14.2 million and higher adjusted EBITDA margins.
Narrative Update • May 19
LFST: Index Additions And Acquisitions Will Support Future Upside
Analysts have raised their price target for LifeStance Health Group to $9.00 from $8, citing updated assumptions around a 7.11% discount rate, 13.84% revenue growth, a 5.96% profit margin, and a 32.29x future P/E multiple. What's in the News LifeStance Health Group is pursuing tuck in acquisitions to enter new metropolitan areas, with management describing a strong pipeline of potential deals and highlighting two new markets opened through acquisitions in the first quarter of 2026 (First Quarter 2026 Earnings Call).Recent updates
Analysis Article • Jun 21
LifeStance Health Group (LFST) Stock Could Be 20% Undervalued After Zacks Rank Upgrade
The latest Zacks upgrade of LifeStance Health Group (LFST) to Rank #1, combined with higher earnings estimates, stronger recent financial results, and rising institutional ownership, has pushed this behavioral health stock firmly into the spotlight. See our latest analysis for LifeStance Health Group. LifeStance Health Group’s recent Zacks Rank upgrade comes alongside strong momentum, with a 30 day share price return of 21.52% and a 1 year total shareholder return of 85.92%, although longer...Narrative Update • Jun 17
LFST: Future Earnings Power Will Rely On Clinician Scale And Technology
Analysts have made a small, neutral adjustment to their price target on LifeStance Health Group to $13.00, reflecting updated assumptions around revenue growth, profit margins and the stock’s projected P/E multiple. What’s in the News for LifeStance Health Group LifeStance Health Group reported Q1 2026 revenue of US$403.5 million, about 21% growth, with net income of US$14.2 million, supported by higher visit volumes, improved clinician productivity and demand for mental health services.Narrative Update • Jun 03
LFST: Future Earnings Power Will Rely On Scalable Clinical Outcomes
Analysts have raised their price target for LifeStance Health Group from $12 to $13, citing updated assumptions around discount rates, profit margins, and future P/E that change their view of the stock's valuation profile. What's in the News Q1 2026 results: Revenue of about US$403.5 million, up 21.2% year over year, with net income of US$14.2 million and higher adjusted EBITDA margins.Narrative Update • May 19
LFST: Index Additions And Acquisitions Will Support Future Upside
Analysts have raised their price target for LifeStance Health Group to $9.00 from $8, citing updated assumptions around a 7.11% discount rate, 13.84% revenue growth, a 5.96% profit margin, and a 32.29x future P/E multiple. What's in the News LifeStance Health Group is pursuing tuck in acquisitions to enter new metropolitan areas, with management describing a strong pipeline of potential deals and highlighting two new markets opened through acquisitions in the first quarter of 2026 (First Quarter 2026 Earnings Call).Narrative Update • Apr 21
LFST: Future Earnings Power Will Rely On Strong Clinical Outcomes
Analysts have modestly adjusted their price target framework for LifeStance Health Group, holding fair value steady at $12.00 while reflecting updated assumptions for revenue growth, profit margins, the discount rate, and future P/E. What's in the News LifeStance Health published clinical outcomes data for nearly 180,000 patients treated for anxiety and depression between September 2024 and December 2025 across 33 states, with 79% of anxiety patients and 73% of depression patients showing clinically significant symptom improvements based on GAD-7 and PHQ-9 assessments (Key Developments).Narrative Update • Apr 07
LFST: Higher Margin Outlook And Repurchase Plan Will Support Future Upside
Analysts have increased their price target on LifeStance Health Group by $8, reflecting updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally lower future P/E multiple. What's in the News LifeStance Health Group filed a follow on equity offering for 25,000,000 shares of its common stock, indicating plans to raise additional equity capital (Key Developments).Narrative Update • Mar 24
LFST: Improved Margins And Buyback Authorization Will Support Stronger Future Upside
Analysts have nudged their price target for LifeStance Health Group higher to reflect updated assumptions for slightly softer revenue growth, improved profit margins and a lower future P/E of 47.12x. What's in the News LifeStance Health Group filed a follow on equity offering for 25,000,000 shares of its common stock, signaling a plan to raise additional capital through the public markets (Key Developments).Narrative Update • Mar 09
LFST: Future Earnings Power Will Rely On Improving Profitability Assumptions
Analysts have raised their price target on LifeStance Health Group to $12.00 from $10.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that together point to a higher estimated fair value. What's in the News LifeStance Health Group filed a follow on equity offering for 25,000,000 shares of its common stock, adding a potential source of new capital for the business (Key Developments).
Narrative Update • Feb 23
LFST: Higher Future P/E Assumption Will Support Stronger Upside Case
Analysts have adjusted their price target for LifeStance Health Group to $9.00 from $8.43, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Updated to $9.00 from $8.43, representing a small upward adjustment in the modelled estimate.Narrative Update • Feb 09
LFST: Improved Margins And Revenue Outlook Will Support Stronger Future Upside
Analysts have modestly lifted their price target on LifeStance Health Group, citing updated assumptions around slightly higher revenue growth, improved profit margins, a small adjustment to the discount rate, and a lower future P/E multiple. Valuation Changes Fair value remains unchanged at US$8.0 per share, indicating no shift in the overall valuation output.Narrative Update • Jan 26
LFST: Calm Referral Partnership And Steady Guidance Will Support Balanced Outlook
Analysts have lifted their price target on LifeStance Health Group to US$8.00 from US$8.00, citing slightly stronger assumptions around revenue growth, profit margins, and a marginally lower future P/E multiple as the key drivers behind the updated view. What's in the News LifeStance Health Group reiterated full year 2025 revenue guidance of US$1.41b to US$1.43b, keeping its top line outlook intact.Narrative Update • Jan 11
LFST: Calm Health Referral Partnership Will Shape Balanced Long Term Outlook
Analysts have raised their fair value estimate for LifeStance Health Group from $6.50 to $8.00, citing updated views on discount rates, revenue growth, profit margin assumptions, and a higher future P/E multiple. What's in the News LifeStance Health Group reiterated its earnings guidance for full year 2025, maintaining expected revenue in the range of $1.41b to $1.43b and updating midpoint expectations for Center Margin to a range of $448 million to $462 million (Corporate guidance).Analysis Article • Nov 22
Market Participants Recognise LifeStance Health Group, Inc.'s (NASDAQ:LFST) Revenues Pushing Shares 26% Higher
LifeStance Health Group, Inc. ( NASDAQ:LFST ) shares have had a really impressive month, gaining 26% after a shaky...Analysis Article • Aug 10
Earnings Update: LifeStance Health Group, Inc. (NASDAQ:LFST) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
It's been a pretty great week for LifeStance Health Group, Inc. ( NASDAQ:LFST ) shareholders, with its shares surging...Seeking Alpha • Jul 03
LifeStance: First Profit, Expanding Margins, And Hybrid Model Make It A Buy Despite Valuation Concerns
Summary LifeStance Health is showing a real turnaround, posting its first-ever net profit and rapidly expanding margins, signaling operational discipline and scalable growth. The company’s hybrid care model positions it well amid surging mental health demand, with strong revenue and clinician growth supporting its bullish outlook. Despite a mixed valuation and recent insider selling, institutional investors are accumulating shares, reflecting confidence in LifeStance’s long-term margin expansion and platform potential. While short-term upside may be limited, I believe LifeStance is undervalued for long-term investors and assign a Buy rating based on its growth trajectory and improving fundamentals. Read the full article on Seeking AlphaAnalysis Article • Jun 25
LifeStance Health Group (NASDAQ:LFST) Is Carrying A Fair Bit Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 22
LifeStance Health Group: Solid Execution Drives Growth And Margin Expansion
Summary I remain bullish on LifeStance Health Group stock due to robust demand, clinician retention, and margin expansion potential, despite recent share price declines. LFST's flexible hybrid care model and digital check-in tool enhance clinician retention and patient accessibility, driving sustainable growth and competitive advantage. LFST's adjusted EBITDA margin reached 10.1% in 4Q24, with management targeting 15-20% over time, supported by operational efficiencies and higher-margin services. Read the full article on Seeking Alpha
New Narrative • Mar 21
Planned Expansions And Clinician-Focused Initiatives Will Improve Future Productivity
Standardizing operations and digital initiatives should enhance efficiency, improve net margins, and boost revenue per visit.Analysis Article • Mar 21
LifeStance Health Group (NASDAQ:LFST) Is Carrying A Fair Bit Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jan 16
LifeStance Health Group, Inc.'s (NASDAQ:LFST) Share Price Matching Investor Opinion
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Analysis Article • Dec 26
Should You Think About Buying LifeStance Health Group, Inc. (NASDAQ:LFST) Now?
LifeStance Health Group, Inc. ( NASDAQ:LFST ), might not be a large cap stock, but it received a lot of attention from...Analysis Article • Dec 05
LifeStance Health Group (NASDAQ:LFST) Is Making Moderate Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Nov 10
Calculating The Intrinsic Value Of LifeStance Health Group, Inc. (NASDAQ:LFST)
Key Insights Using the 2 Stage Free Cash Flow to Equity, LifeStance Health Group fair value estimate is US$6.52 With...Analysis Article • Sep 26
Why Investors Shouldn't Be Surprised By LifeStance Health Group, Inc.'s (NASDAQ:LFST) P/S
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Analysis Article • Sep 02
Here's Why LifeStance Health Group (NASDAQ:LFST) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 11
LifeStance Health Group, Inc. (NASDAQ:LFST) Just Reported Earnings, And Analysts Cut Their Target Price
Last week saw the newest second-quarter earnings release from LifeStance Health Group, Inc. ( NASDAQ:LFST ), an...Analysis Article • Jul 15
LifeStance Health Group, Inc.'s (NASDAQ:LFST) Intrinsic Value Is Potentially 63% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, LifeStance Health Group fair value estimate is US$8.70 Current...Analysis Article • Jun 07
With LifeStance Health Group, Inc. (NASDAQ:LFST) It Looks Like You'll Get What You Pay For
LifeStance Health Group, Inc.'s ( NASDAQ:LFST ) price-to-sales (or "P/S") ratio of 2x may not look like an appealing...Seeking Alpha • May 23
LifeStance: Selloff Opens Buying Opportunity Thanks To Price/Value Dislocation
Summary Shares of LifeStance Health plunged over 20% after a secondary offering of 20 million shares at $6.25 per share. LifeStance's Q1 earnings showed strong sales growth and projected double-digit top-line growth for the next three years. The sell-off has created a buying opportunity as LFST stock's valuation is dislocated from its potential growth and is trading at a discount. Read the full article on Seeking AlphaShareholder Returns
| LFST | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 4.5% | -2.4% | 1.4% |
| 1Y | 81.0% | 17.6% | 25.7% |
Return vs Industry: LFST exceeded the US Healthcare industry which returned 17.6% over the past year.
Return vs Market: LFST exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| LFST volatility | |
|---|---|
| LFST Average Weekly Movement | 8.8% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LFST has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LFST's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 8,349 | Dave Bourdon | lifestance.com |
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder.
LifeStance Health Group, Inc. Fundamentals Summary
| LFST fundamental statistics | |
|---|---|
| Market cap | US$3.48b |
| Earnings (TTM) | US$23.20m |
| Revenue (TTM) | US$1.49b |
150.1x
P/E Ratio2.3x
P/S RatioIs LFST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LFST income statement (TTM) | |
|---|---|
| Revenue | US$1.49b |
| Cost of Revenue | US$1.01b |
| Gross Profit | US$487.24m |
| Other Expenses | US$464.04m |
| Earnings | US$23.20m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.06 |
| Gross Margin | 32.60% |
| Net Profit Margin | 1.55% |
| Debt/Equity Ratio | 19.0% |
How did LFST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/22 19:46 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LifeStance Health Group, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephanie Davis | Barclays |
| Peter Warendorf | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |